Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Hepatocellular Carcinoma (HCC) Clinical Trial

Official title:

Efficacy and Safety of Lenvatinib as a Conversion Therapy in Patients With Potentially Resectable Hepatocellular Carcinoma: A Single-Arm and Open-Label Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04241523
• Other study ID #: HCC-LEN-Conversion
• Status: Recruiting
• Phase: Phase 2
• Start date: January 2020
• Est. completion date: February 2022

Study information

• Verified date: January 2020
• Source: Shanghai Zhongshan Hospital
• Contact: Jian Zhou
• Phone: 0086-21-64041990
• Email: zhou.jian[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in patients with potential resectable HCC and improve the long term survival.

Description:

For patients with potentially resectable HCC (intermediate or advanced stage), upfront therapy with surgical resection is of high recurrence rate after surgery. The aim of the single-arm, open-label, prospective phase II clinical trial is to evaluate whether preoperative lenvatinib treatment could improve resectability and therefore improve the long term survival.

Participants who are recruited in this study in this study will be treated with lenvatinib and will be evaluated for the feasibility for surgical resection by a multidisciplinary team every 8 weeks. If the participants underwent curative resection, they will receive lenvatinib treatment for 48 weeks after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 2022
• Est. primary completion date: October 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female aged 18-75;

2. The participant must have confirmed diagnosis of HCC histologically or clinically;

3. The participant must have at least one untreated intrahepatic lesion that can be evaluated by contrast-enhanced CT or MRI;

4. The BCLC stage B/C patients, more than 3 tumor nodes or have portal vein tumor thrombus (Vp3-Vp4 according to LCSGJ PVTT classification) or extrahepatic metastases limited to one organ and the number of metastases nodules is no more than 3;

5. ECOG PS 0-1 and Child-Pugh A;

6. Surgical resection is not the first choice according to MDT evaluation;

7. Written informed consent;

Exclusion Criteria:

1. WBC<4.0*10^9/L, HB<80 g/L, PLT<75*10^9/L and NEUT<1.5×10^9/L;

2. Coagulation function: (prothrombin time) international normalized ratio (INR) >1.2;

3. Liver function: serum albumin (ALB)<3.5 g/dl, total bilirubin (TBIL)>1.5 times the upper limit of normal range, alanine aminotransferase and aspartate aminotransferase (ALT and AST)>3 times the upper limit of normal range; renal function index: serum creatinine (CRE)>1.5 times the upper limit of normal range; uncontrolled hypertension (>150/90mm Hg);

4. Lymph node metastasis to hilar of lung or liver, or peripheral tissue adhesion;

5. Participated in other clinical trials 30 days before enrollment;

6. With ascites, hepatic encephalopathy, Gilbert syndrome, sclerosing cholangitis;

7. Suspected allergy to study drug;

8. With other organ dysfunction, it is not expected to be tolerated general anesthesia or hepatectomy;

9. Other conditions that the investigators considered not unsuitable for inclusion.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma (HCC)

Intervention

Drug:
• Lenvatinib 4 mg Oral
Planned doses of 8 mg of lenvatinib per day for patients with body weight <60 kg, and 12 mg for those with body weight =60 kg. In case of treatment-related adverse effects, interruption or reduction is allowed.

Locations

Country	Name	City	State
China	West China Hospital	Chengdu	Sichuan
China	Anhui Provincial Hospital	Hefei	Anhui
China	180 Fenglin Road	Shanghai
China	Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (4)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital	Anhui Provincial Hospital, Tongji Hospital, West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resection rate	The percentage of patients who receive curative liver resection for HCC. The criteria for curative resection: (1) no active tumor thrombosis is observed in hepatic veins, portal veins, bile ducts or inferior vena cava; or the type of portal vein invasion was converted from Vp3/Vp4 to Vp1/Vp2; (2) no active metastasis to adjacent organs or distant organs, or to lymph nodes; (3) the surgical margin = 0.5 cm; (4) the number of active tumor nodules decreases from =4 to <4; (5) the ratio of future liver volume to standard liver volume increases from <40% to =40% (for those with liver cirrhosis) or from <30% to =30% (for those without liver cirrhosis).	1 year after LPI
Secondary	Overall survival (OS)	The duration from the date of recruitment to the date of death from any cause.	3 years
Secondary	Objective response rate (ORR)	ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters)	1 year after LPI
Secondary	Serum Biomarkers	To explore the relationship between the baseline level and dynamic changes of serum markers(AFP and PIVKA-II) and therapeutic response, Peripheral blood serum was collected at baseline and at each follow-up visit.	1 year after LPI
Secondary	Adverse events(AE) and Serious adverse events(SAE)	An adverse event (AE) refers to any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, but which does not necessarily have a causal relationship with this treatment.; A serious adverse event (SAE) refers to an event in clinical trials that requires inpatient hospitalization or causes prolongation of existing hospitalization, permanent disability, incapacity, threats to life or death, and birth defect, etc.; Number and classification of participants with treatment-related adverse events as assessed by CTCAE v4.0 were recorded.	1 year after LPI
Secondary	Health-related quality of life: EORTC QLQ-HCC18	Health-related quality of life questionnaire measured by EORTC QLQ-HCC18.	1 year after LPI
Secondary	Exploratory serum biomarker research	About 10 mL peripheral blood will be collected at baseline and at each follow-up visit. The correlations between serum biomarkers at baseline or the dynamic changes and treatment response will be analyzed.	1 year after LPI